• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    1/19/23 12:30:58 PM ET
    $ANPC
    $APGN
    $BDTX
    $BLCM
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANPC alert in real time by email

    Gainers

    • BeyondSpring (NASDAQ:BYSI) stock moved upwards by 24.4% to $2.7 during Thursday's regular session. Trading volume for BeyondSpring's stock is 1.2 million as of 12:30 EST. This is 132.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $105.1 million.
    • Concert Pharma (NASDAQ:CNCE) shares rose 20.28% to $8.3. The current volume of 44.2 million shares is 9544.2% of Concert Pharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $397.8 million.
    • Bellicum Pharmaceuticals (NASDAQ:BLCM) shares moved upwards by 17.93% to $1.25. Bellicum Pharmaceuticals's stock is trading at a volume of 294.3K shares as of 12:30 EST. This is 1178.7% of its average full-day volume over the last 100 days. The company's market cap stands at $10.7 million.
    • AnPac Bio-Medical Science (NASDAQ:ANPC) stock increased by 14.91% to $10.2. Trading volume for this security as of 12:30 EST is 150.1K, which is 374.8% of its average full-day volume over the last 100 days. The company's market cap stands at $416.2 million.
    • Apexigen (NASDAQ:APGN) shares increased by 13.19% to $2.03. Trading volume for Apexigen's stock is 7.3 million as of 12:30 EST. This is 416.0% of its average full-day volume over the last 100 days. The company's market cap stands at $45.7 million.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) shares moved upwards by 12.49% to $1.17. As of 12:30 EST, this security is trading at a volume of 5.8 million shares, making up 91.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $67.3 million.

    Losers

    • Aceragen (NASDAQ:ACGN) shares declined by 32.9% to $5.8 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume of 155.6K shares, making up 13.8% of its average full-day volume over the last 100 days. The company's market cap stands at $21.2 million.
    • Surmodics (NASDAQ:SRDX) stock declined by 30.21% to $26.06. As of 12:30 EST, this security is trading at a volume of 307.2K shares, making up 709.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $368.1 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock fell 26.99% to $4.6. Trading volume for this security as of 12:30 EST is 1.2 million, which is 172.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $182.8 million.
    • Black Diamond Therapeutic (NASDAQ:BDTX) stock decreased by 23.77% to $2.39. As of 12:30 EST, this security is trading at a volume of 300.8K shares, making up 145.4% of its average full-day volume over the last 100 days. The company's market cap stands at $87.0 million.
    • GeneDx Holdings (NASDAQ:WGS) shares decreased by 20.76% to $0.36. Trading volume for this security as of 12:30 EST is 1.6 million, which is 84.3% of its average full-day volume over the last 100 days. The company's market cap stands at $138.5 million.
    • Hepion Pharmaceuticals (NASDAQ:HEPA) stock fell 20.58% to $0.63. Trading volume for Hepion Pharmaceuticals's stock is 3.1 million as of 12:30 EST. This is 492.2% of its average full-day volume over the last 100 days. The company's market cap stands at $48.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANPC
    $APGN
    $BDTX
    $BLCM

    CompanyDatePrice TargetRatingAnalyst
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    11/18/2025$9.00Overweight
    Piper Sandler
    Surmodics Inc.
    $SRDX
    11/14/2025Mkt Perform → Underperform
    Barrington Research
    Black Diamond Therapeutics Inc.
    $BDTX
    10/16/2025$8.00Buy
    Stifel
    Black Diamond Therapeutics Inc.
    $BDTX
    9/4/2025$8.00Buy
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    7/1/2025$11.00Outperform
    Raymond James
    Surmodics Inc.
    $SRDX
    3/7/2025$43.00Hold → Buy
    Lake Street
    Black Diamond Therapeutics Inc.
    $BDTX
    7/31/2024$20.00Outperform
    Raymond James
    More analyst ratings

    $ANPC
    $APGN
    $BDTX
    $BLCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Morris Jessica Edgar

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    2/26/26 7:03:32 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Saenger Bradley

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    2/26/26 7:03:05 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Sullivan Gregory M

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    2/26/26 7:02:37 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANPC
    $APGN
    $BDTX
    $BLCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Taylor Carolyn E. bought $15,061 worth of shares (418 units at $36.03) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/21/25 5:22:56 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Treco James bought $9,000 worth of shares (250 units at $36.00) (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    8/20/25 4:15:15 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Lederman Seth bought $86,200 worth of shares (4,000 units at $21.55), increasing direct ownership by 80,000% to 4,005 units (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    5/15/25 5:08:40 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANPC
    $APGN
    $BDTX
    $BLCM
    SEC Filings

    View All

    SEC Form 10-K filed by Tonix Pharmaceuticals Holding Corp.

    10-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    3/12/26 5:29:52 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Hepion Pharmaceuticals Inc.

    10-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

    3/11/26 9:43:19 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    3/10/26 8:05:34 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANPC
    $APGN
    $BDTX
    $BLCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA to patients, approximately 2,500 patients have initiated treatment with TONMYA, and cumulative prescriptions totaled approximately 4,200 Expect to initiate U.S. field study in 2027 for TNX-4800 for seasonal prevention of Lyme disease pending FDA clearance Completed $20.0 million registered direct offering with Point72 on December 29, 2025 Approximately $207.6 million in cash and cash equivalents as of December 31, 2025 BERKELEY HEIGHTS, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmac

    3/12/26 5:30:00 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

    Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of treatment, with durable pain reduction and significant improvements in all key secondary endpoints as compared to placebo In pooled post hoc analysis of the pivotal RELIEF and RELISIENT studies, TONMYA showed favorable benefit-risk profile using number needed to treat, number needed to harm, and likelihood to be helped or harmed BERKELEY HEIGHTS, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, com

    3/10/26 8:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANPC
    $APGN
    $BDTX
    $BLCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Black Diamond Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics from Buy to Neutral

    12/3/25 12:43:23 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler resumed coverage on Black Diamond Therapeutics with a new price target

    Piper Sandler resumed coverage of Black Diamond Therapeutics with a rating of Overweight and set a new price target of $9.00

    11/18/25 8:20:21 AM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Surmodics downgraded by Barrington Research

    Barrington Research downgraded Surmodics from Mkt Perform to Underperform

    11/14/25 11:19:52 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $ANPC
    $APGN
    $BDTX
    $BLCM
    Financials

    Live finance-specific insights

    View All

    Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

    Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to datePFS data for 1L NSCLC patients expected in Q2 2026; Company continues to explore partnership opportunities for pivotal development of silevertinibBased on encouraging CNS activity of silevertinib in multiple trials across NSCLC and GBM, Company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed GBM patients in 1H 2026; initial data anticipated in 2028Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025;

    12/3/25 7:01:00 AM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

    Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo; generally well tolerated Commercial availability of Tonmya is expected in the fourth quarter Company to host webcast and conference call on Monday August 18, 2025 at 8:30 AM ET CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administratio

    8/15/25 3:44:52 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

    Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon ("DCB") license fee revenue(1) of $29.6 million, an increase of 1% year-over-year GAAP loss of $(5.3) million, compared to $(7.6) million in the prior-year period Adjusted EBITDA(2) of $3.4 million, compared to $1.6 million in the pr

    8/8/25 7:00:00 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $ANPC
    $APGN
    $BDTX
    $BLCM
    Leadership Updates

    Live Leadership Updates

    View All

    Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

    CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025. Ms. Ishak will lead Tonix's legal, corporate governance, and compliance functions. "Irina is a highly accomplished corporate and commercial attorney whose experience spans public and private life sciences companies, as well as advising life sciences investors," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. "Her deep background in complex transactions, public company matters, and governa

    12/9/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

    Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million reported as of September 30, 2025; current cash runway expected to fund operations into the first quarter of 2027 CHATHAM, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial biotechnology company today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent operational highlights. "Following U.S. Food a

    11/10/25 4:15:00 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

    Mr. Kamath brings more than 25 years of market access, pricing, and commercial operations experience to Tonix On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, the first new fibromyalgia therapy in more than 15 years US Launch of Tonmya expected in the fourth quarter of 2025 CHATHAM, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the appointment of Ganesh Kamath as Head of Market Access

    9/30/25 8:30:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANPC
    $APGN
    $BDTX
    $BLCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:42:22 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care